199 related articles for article (PubMed ID: 10770555)
1. The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen.
Leitz G; Robinson P
AIDS; 2000 Mar; 14(4):468-9. PubMed ID: 10770555
[No Abstract] [Full Text] [Related]
2. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
Brinkman K; Smeitink JA; Romijn JA; Reiss P
Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
[TBL] [Abstract][Full Text] [Related]
3. Lipodystrophy--nukes vs. protease inhibitors.
TreatmentUpdate; 2001 Jul; 13(3):5-6. PubMed ID: 11569989
[No Abstract] [Full Text] [Related]
4. PI/NRTI "sparing" regimens for HIV infection. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
Cohen C
IAPAC Mon; 2001 Aug; 7(8):254-60. PubMed ID: 11708281
[No Abstract] [Full Text] [Related]
5. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
[TBL] [Abstract][Full Text] [Related]
6. Substitution for protease inhibitors in HIV therapy.
Mikhail E
N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14689602
[No Abstract] [Full Text] [Related]
7. New anti-HIV drug interactions, toxicities, and dosing options.
Bartnof HS
BETA; 1999; 12(4):60-3, 66. PubMed ID: 11367260
[TBL] [Abstract][Full Text] [Related]
8. Lipodystrophy associated with nevirapine-containing antiretroviral therapies.
Aldeen T; Wells C; Hay P; Davidson F; Lau R
AIDS; 1999 May; 13(7):865-7. PubMed ID: 10357391
[No Abstract] [Full Text] [Related]
9. HIV lipodystrophy: a review.
Kravcik S
HIV Clin Trials; 2000; 1(3):37-50. PubMed ID: 11590504
[TBL] [Abstract][Full Text] [Related]
10. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
11. Focus on fat.
TreatmentUpdate; 2002 Nov; 14(8):4. PubMed ID: 12501822
[No Abstract] [Full Text] [Related]
12. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
Carr A; Miller J; Law M; Cooper DA
AIDS; 2000 Feb; 14(3):F25-32. PubMed ID: 10716495
[TBL] [Abstract][Full Text] [Related]
13. Nonnucleoside reverse transcriptase inhibitors.
Murphy RL
AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
[TBL] [Abstract][Full Text] [Related]
14. Simplifying suppression: switching therapies to improve HIV disease management.
Moyle GJ
AIDS Read; 2004 Jul; 14(7):380-4. PubMed ID: 15282867
[No Abstract] [Full Text] [Related]
15. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
16. Standard treatments for HIV, Spring 1997.
Smith D
AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
[TBL] [Abstract][Full Text] [Related]
17. Choosing the right initial antiretroviral regimens.
Norton M
GMHC Treat Issues; 1999 Feb; 13(2):7-10. PubMed ID: 11366117
[TBL] [Abstract][Full Text] [Related]
18. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus.
Paparizos VA; Kyriakis KP; Botsis C; Papastamopoulos V; Hadjivassiliou M; Stavrianeas NG
AIDS; 2000 May; 14(7):903-5. PubMed ID: 10839604
[No Abstract] [Full Text] [Related]
19. Complete reversibility of severe nucleoside-induced lipodystrophy.
Strobel M; Muller P; Claudel P
AIDS; 1999 Dec; 13(18):2606-7. PubMed ID: 10630538
[No Abstract] [Full Text] [Related]
20. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
